Terns Pharmaceuticals, Inc. Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

TERN

주식 순위 #3584
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
주가
$52.95
마지막 동기화: 2026-05-15
시가총액
$4.77B
변동 (1일)
0.00%
변동 (1년)
529.61%
국가
US
거래 Terns Pharmaceuticals, Inc. (TERN)

카테고리

Healthcare
Terns Pharmaceuticals, Inc. (TERN)의 EPS
December 2025 기준 EPS TTM: $-1.03
Terns Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-1.03입니다. 2023년 말에는 회사의 EPS가 $-1.27였으며, 이는 2022년의 EPS $-1.67와 감소입니다.
Terns Pharmaceuticals, Inc.의 EPS 기록 (2018 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2026 (TTM) $-1.03 -8.04%
2024 $-1.12 -11.81%
2023 $-1.27 -23.95%
2022 $-1.67 -15.66%
2021 $-1.98 22.98%
2020 $-1.61 -41.24%
2019 $-2.74 270.27%
2018 $-0.74 0.00%
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -1,781.55%
US
$-7.98 674.76%
US
$-5.29 413.59%
AU
- -
CH
$27.74 -2,793.20%
NL